Dingdong (NYSE:DDL) has agreed to sell its core Chinese fresh grocery business to a subsidiary of Meituan, marking a dramatic retreat for the New York-listed firm as it pivots to international markets to escape China’s cutthroat e-commerce price wars.
HIVE Digital Technologies (NASDAQ:HIVE) reported a massive jump in January production, fueled by a tripling of its mining capacity and the rapid deployment of high-efficiency hardware at its flagship South American facilities.
Alvotech (NASDAQ:ALVO) announced positive top-line results from a pivotal clinical study for its biosimilar candidate to Entyvio, positioning the Icelandic biotech to challenge one of the top-selling gastrointestinal treatments in a $6.4 billion market.
Luxembourg-based ArcelorMittal (NYSE:MT), the world’s leading steel and mining company, reported financial results for the full year ended December 31, 2025.
In times of uncertainty, we often look for something solid to hold onto. Lately, it seems the world’s investors have decided that “something solid” is, quite literally, gold.
The metal’s soaring price is more than just a market trend; it's a global barometer of anxiety.
When faith in currencies, governments, and traditional financial systems begins to waver, we see a familiar flight to the perceived safety of this timeless asset.
Well, pull out the party hats and dust off the stock tickers.
Lithium, the commodity that investors and analysts had all but left for dead in the great market purge of 2023-2024, is back.
The stock market has long treated Tesla (NASDAQ:TSLA) less as a traditional automaker and more as a futuristic technology cult, with its valuation soaring on the gravitational pull of its CEO, Elon Musk.
This persistent "Musk Premium" has burned countless short-sellers.
Bitcoin has vaporised more than US$800 billion in its latest crash and sucked US$1 trillion out of the broader crypto market.
With nearly US$2 trillion in market value and rising allocations from Wall Street firms, ETFs, pension funds, and insurers, Bitcoin is increasingly woven into traditional finance.
Trump used his Davos speech to tout US economic dominance, promote crypto, and revive his push for Greenland.
Japan’s bond market has been sliding all week, with the 10-year yield now near 2.37% and the 40-year pushing above 4.2%, both multi-decade highs.
U.S. President Donald Trump has escalated his confrontation with European leaders on the eve of the World Economic Forum in Davos, threatening to impose a 200% tariff on French wine and champagne.
Eli Lilly (NYSE:LLY) delivered a blowout fourth-quarter report and a massive 2026 forecast that solidified its position as the world’s most valuable healthcare company, fueled by the explosive growth of its tirzepatide franchise.
Uber Technologies (NYSE:UBER) accelerated to a record-breaking finish in 2025, reaching a milestone of 200 million monthly active users and delivering a 130% surge in quarterly operating income.
GE HealthCare Technologies (NASDAQ:GEHC) delivered a strong finish to 2025, reporting fourth-quarter sales that outpaced expectations and providing a 2026 forecast that signals continued margin expansion for the medical-tech giant.
AbbVie (NYSE:ABBV) delivered a robust full-year performance for 2025, proving that its strategy to replace the aging blockbuster Humira is ahead of schedule as its newer immunology and neuroscience portfolios hit record highs.
Novo Nordisk (NYSE:NVO) reported fourth-quarter results on Wednesday that exceeded analyst expectations, but shares plummeted as the Danish pharmaceutical giant issued a "shocking" outlook for 2026, warning of a potential double-digit decline in sales and profit.
Alphabet (NASDAQ:GOOGL) reported fourth-quarter results that handily beat Wall Street expectations, as the search giant proved that its heavy investments in generative AI are beginning to pay off through resurgent advertising growth and a surging cloud business.
GSK (NYSE:GSK) reported fourth-quarter results that cleared Wall Street estimates, as the British drugmaker successfully leveraged its high-growth specialty medicines to offset slowing demand for its flagship RSV vaccine, Arexvy.
Boston Scientific (NYSE:BSX) reported fourth-quarter results that topped analyst estimates, driven by a double-digit surge in its cardiovascular division and a string of regulatory wins that are reshaping its competitive landscape.
-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)
